+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030- Product Image
Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030- Product Image
Sale

Respiratory Disease Testing Market by Test Type (Blood Tests, Imaging Tests, Pulmonary Function Tests), Component (Instruments, Reagents & Kits, Software), Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012368
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Respiratory Disease Testing Market grew from USD 6.49 billion in 2024 to USD 6.86 billion in 2025. It is expected to continue growing at a CAGR of 5.95%, reaching USD 9.18 billion by 2030.

Understanding the Imperative and Objectives of Respiratory Disease Testing Trends and Strategic Framework for Informed Decision Making

With the global prevalence of respiratory ailments escalating across demographic and geographic boundaries, a comprehensive understanding of diagnostic testing dynamics has become indispensable. The surge in chronic conditions such as asthma and COPD, coupled with recurrent infectious outbreaks like influenza and tuberculosis, underscores the urgent demand for robust testing frameworks. Against this evolving backdrop, stakeholders-from diagnostic laboratories to hospital networks-are compelled to adopt advanced methodologies that ensure accuracy, efficiency, and scalability.

This summary delineates the critical drivers shaping diagnostic innovation, highlights the regulatory and geopolitical shifts impacting supply chains, and illuminates the competitive landscape governed by instrument developers, reagent manufacturers, and software solution providers. By examining segment-specific trends across a wide array of test types, technologies, and end-user channels, it equips decision-makers with the insights necessary to refine product pipelines, optimize operations, and anticipate future disruptions. Ultimately, this introduction establishes the strategic foundation for a deep dive into the transformative forces and actionable imperatives defining respiratory disease testing today

Examining the Transformative Technological Regulatory and Epidemiological Shifts Redefining Respiratory Disease Testing Through 2025

Over the past decade, technological breakthroughs have converged with shifting regulatory paradigms to redefine the respiratory disease testing ecosystem. Laboratory automation and digital imaging innovations now enable high-throughput workflows, while artificial intelligence-driven algorithms are enhancing diagnostic precision by identifying subtle pathophysiological markers. In parallel, evolving standards from agencies such as the FDA and EMA have accelerated the approval of novel molecular assays, prompting manufacturers to design platforms that meet stringent quality and interoperability requirements.

Moreover, the global emphasis on pandemic preparedness has elevated the strategic importance of multiplex testing, portable point-of-care devices, and telemonitoring solutions. These developments have not only fortified clinical responsiveness to emergent pathogens but have also catalyzed investments in decentralized testing infrastructures. Consequently, industry participants must navigate the delicate balance between innovation agility and compliance rigor to capture new market opportunities.

Analyzing the Multifaceted Cumulative Impact of 2025 United States Tariffs on Supply Chains Costs and Innovation in Respiratory Disease Diagnostics

The implementation of new United States tariff structures in 2025 has reverberated throughout the respiratory diagnostics supply chain, exerting pressure on reagent pricing and equipment procurement. Increased duties on imported raw materials have compelled reagent suppliers to reassess sourcing strategies, leading some to establish regional manufacturing hubs to mitigate cost volatility. Simultaneously, instrument developers are renegotiating contracts with key component vendors to preserve margin integrity without compromising on performance standards.

These tariff-driven adjustments have also accelerated conversations around nearshoring and strategic alliances, as stakeholders seek to bolster supply chain resilience. While some companies have absorbed incremental cost burdens through internal efficiency gains, others have prioritized the development of reagentless or open-platform technologies that reduce dependency on specialized imports. Going forward, entities that proactively adapt to this new tariff environment by diversifying vendor portfolios and optimizing logistics networks will be best positioned to sustain growth and preserve competitive advantage.

Revealing Actionable Insights from Multidimensional Test Type Component Age Group Technology Purpose Disease Type and End User Segmentations

Delving into test type segmentation reveals a market dominated by blood-based assays that facilitate routine biomarker monitoring, while imaging tests-including both chest X-ray and computed tomography-offer critical anatomical insights for acute diagnostics. Pulmonary function tests continue to serve as a foundational tool for evaluating lung capacity and disease progression. When considering components, instruments form the capital-intensive backbone of diagnostic workflows, whereas reagents and kits drive recurring revenue streams and software solutions increasingly underpin data management and remote collaboration.

Further granularity emerges through age group analysis, where adult testing volumes remain substantial, geriatric cohorts demand specialized protocols due to comorbidities, and pediatric populations require tailored reagent sensitivities and sample volumes. Technological segmentation highlights the growing penetration of imaging modalities, immunoassays, microbiology platforms, and molecular diagnostics that collectively elevate diagnostic accuracy. Examining test purpose, diagnostic applications lead adoption, while monitoring assays enable longitudinal patient management, prognostic tools guide therapeutic decision-making, and screening programs support early detection initiatives.

Disease type distinctions underscore the prevalence of asthma and chronic obstructive pulmonary disease-with subcategories of chronic bronchitis and emphysema-alongside infectious respiratory diseases such as influenza, pneumonia, and tuberculosis. Lung cancer testing, leveraging advanced molecular and imaging approaches, represents a critical area of unmet clinical need. End user segmentation spans diagnostic laboratories with high-throughput capabilities, home care settings that facilitate patient-centric monitoring, hospitals and clinics providing acute care, and research laboratories pioneering next-generation assays.

Uncovering Regional Dynamics and Growth Potential Across Americas Europe Middle East Africa and Asia-Pacific in Respiratory Disease Testing

Regional dynamics in respiratory disease testing reveal distinct growth trajectories and investment priorities across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. In the Americas, robust healthcare infrastructure and favorable reimbursement policies have fostered rapid adoption of high-precision molecular and imaging technologies. Stakeholders in Europe, the Middle East, and Africa balance regulatory harmonization efforts with resource variability, driving demand for adaptable point-of-care solutions that can bridge urban and rural care gaps. Across Asia-Pacific, burgeoning healthcare expenditure, expanding diagnostic networks, and targeted government initiatives against infectious diseases have catalyzed significant uptake of both established and emerging testing modalities.

These regional nuances underscore the importance of localized market entry strategies, partnerships with governmental and non-profit bodies, and investments in training and support services to ensure sustained adoption. Additionally, logistical considerations-ranging from reagent cold-chain management to equipment maintenance-vary significantly by region, necessitating comprehensive distribution and service models tailored to each territory’s unique operational context.

Profiling Key Industry Leaders Their Innovations Collaborations and Strategic Initiatives Shaping the Respiratory Disease Testing Market

Key industry participants are leveraging a combination of strategic collaborations, product line expansions, and digital health integrations to consolidate their leadership positions. Legacy instrument providers are complementing core diagnostic platforms with cloud-enabled analytics, while reagent specialists are forging partnerships to co-develop multiplex assay panels. Concurrently, software developers are collaborating with clinical laboratories to deliver end-to-end workflow solutions that enhance traceability and compliance.

In addition, smaller disruptive ventures are attracting investment for their innovative point-of-care devices and AI-driven diagnostic engines. These emerging players are forging alliances with established manufacturers to scale commercialization efforts and navigate complex regulatory pathways. Across the competitive landscape, the synergies between instrument vendors, reagent manufacturers, and software integrators are reshaping value chains, fostering an ecosystem in which interoperability and data interoperability serve as critical differentiators.

Formulating Actionable Strategic Recommendations to Drive Competitive Advantage and Accelerate Innovation in Respiratory Disease Testing Industry

To maintain a competitive edge, industry leaders should prioritize the integration of artificial intelligence and machine learning into diagnostic workflows to deliver enhanced analytic precision and predictive capabilities. Moreover, diversifying supply chains through regional production facilities and alternative raw-material sourcing agreements will reinforce resilience against geopolitical disruptions. Embracing decentralized testing strategies-such as at-home monitoring and portable point-of-care units-can extend service delivery into underserved areas while alleviating laboratory backlogs.

Furthermore, cultivating partnerships across public and private sectors will accelerate product adoption and facilitate reimbursement pathways. Investing in modular platforms that accommodate multiplex assays enables seamless adaptation to emerging pathogens and evolving clinical guidelines. Lastly, by engaging regulatory bodies early in the development cycle, organizations can expedite approvals and ensure compliance, ultimately accelerating time to market and delivering timely solutions to patients and healthcare providers.

Detailing the Rigorous Research Methodology Data Sources and Analytical Approaches Underpinning Respiratory Disease Testing Market Insights

The research methodology employed a multi-stage process beginning with exhaustive secondary research across peer-reviewed journals, regulatory databases, and corporate filings to compile a foundational dataset. This was followed by primary interviews with a cross-section of stakeholders-including senior executives at diagnostic laboratories, R&D heads at instrument manufacturers, healthcare policy experts, and leading academics-to validate findings and gather qualitative insights.

Quantitative analysis involved the triangulation of data points using both top-down and bottom-up approaches to assess technology adoption patterns, disease prevalence correlations, and end-user requirements. Data integrity was ensured through rigorous cross-validation techniques, while analytical models incorporated sensitivity analyses to account for varying regulatory and economic scenarios. The methodology culminated in the synthesis of thematic insights, competitive benchmarking, and scenario planning to deliver a robust framework for strategic decision-making.

Synthesizing Core Findings and Strategic Imperatives to Guide Stakeholders Through the Evolving Respiratory Disease Testing Landscape

In summation, the respiratory disease testing arena is undergoing a transformative phase driven by technological innovations, evolving regulatory standards, and shifting supply chain dynamics. Stakeholders are challenged to balance rapid adoption of advanced diagnostics with the operational complexities introduced by new tariffs and regional disparities. At the same time, emerging AI solutions and decentralized testing models present unparalleled opportunities for enhancing patient outcomes and streamlining clinical workflows.

By aligning strategic investments with segmentation insights and regional priorities, organizations can unlock new avenues for growth while fortifying resilience against future disruptions. The interplay between established leaders and nimble disruptors will continue to shape the competitive landscape, underscoring the importance of agility and collaborative innovation as core pillars for success in this rapidly evolving market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Test Type
    • Blood Tests
    • Imaging Tests
      • Chest X-Ray
      • Computed Tomography
    • Pulmonary Function Tests
  • Component
    • Instruments
    • Reagents & Kits
    • Software
  • Age Group
    • Adults
    • Geriatrics
    • Pediatrics
  • Technology
    • Imaging Technologies
    • Immunoassays
    • Microbiology
    • Molecular Diagnostics
  • Test Purpose
    • Diagnosis
    • Monitoring
    • Prognosis
    • Screening
  • Diseases Type
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
      • Chronic Bronchitis
      • Emphysema
    • Infectious Respiratory Diseases
      • Influenza
      • Pneumonia
      • Tuberculosis
    • Lung Cancer
  • End Users
    • Diagnostic Laboratories
    • Home Care Settings
    • Hospitals & Clinics
    • Research Laboratories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of CRISPR-based point-of-care assays for rapid detection of respiratory pathogens
5.2. Deployment of AI-driven algorithms for predictive respiratory infection risk assessment in clinical settings
5.3. Adoption of telehealth-integrated home sampling kits enhancing remote respiratory diagnostics capabilities
5.4. Growth of multiplex PCR panels targeting emerging airborne pathogen variants in hospital laboratories
5.5. Rising use of wearable breath analysis devices for continuous monitoring of respiratory biomarkers in real time
5.6. Implementation of cloud-connected testing platforms enabling real-time surveillance of respiratory outbreaks
5.7. Increased development of paper-based lateral flow assays for low-cost respiratory virus screening in emerging markets
5.8. Emergence of next-generation sequencing workflows for comprehensive respiratory microbiome profiling and pathogen discovery
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Respiratory Disease Testing Market, by Test Type
8.1. Introduction
8.2. Blood Tests
8.3. Imaging Tests
8.3.1. Chest X-Ray
8.3.2. Computed Tomography
8.4. Pulmonary Function Tests
9. Respiratory Disease Testing Market, by Component
9.1. Introduction
9.2. Instruments
9.3. Reagents & Kits
9.4. Software
10. Respiratory Disease Testing Market, by Age Group
10.1. Introduction
10.2. Adults
10.3. Geriatrics
10.4. Pediatrics
11. Respiratory Disease Testing Market, by Technology
11.1. Introduction
11.2. Imaging Technologies
11.3. Immunoassays
11.4. Microbiology
11.5. Molecular Diagnostics
12. Respiratory Disease Testing Market, by Test Purpose
12.1. Introduction
12.2. Diagnosis
12.3. Monitoring
12.4. Prognosis
12.5. Screening
13. Respiratory Disease Testing Market, by Diseases Type
13.1. Introduction
13.2. Asthma
13.3. Chronic Obstructive Pulmonary Disease (COPD)
13.3.1. Chronic Bronchitis
13.3.2. Emphysema
13.4. Infectious Respiratory Diseases
13.4.1. Influenza
13.4.2. Pneumonia
13.4.3. Tuberculosis
13.5. Lung Cancer
14. Respiratory Disease Testing Market, by End Users
14.1. Introduction
14.2. Diagnostic Laboratories
14.3. Home Care Settings
14.4. Hospitals & Clinics
14.5. Research Laboratories
15. Americas Respiratory Disease Testing Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Respiratory Disease Testing Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Respiratory Disease Testing Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. AstraZeneca PLC
18.3.3. Becton, Dickinson and Company
18.3.4. Bio-Rad Laboratories, Inc.
18.3.5. Biomérieux PLC
18.3.6. Charles River Laboratories
18.3.7. COSMED srl
18.3.8. Eurofins Viracor, LLC
18.3.9. F. Hoffmann-La Roche Ltd.
18.3.10. Fujifilm Holdings
18.3.11. GE Healthcare
18.3.12. Koninklijke Philips N.V
18.3.13. Medtronic PLC
18.3.14. MGC Diagnostics Corporation by Caire Inc.
18.3.15. QIAGEN Group
18.3.16. ResMed
18.3.17. SDI Diagnostics, Inc.
18.3.18. Seegene Inc.
18.3.19. Seimens Healthineers AG
18.3.20. Thermo Fisher Scientific
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. RESPIRATORY DISEASE TESTING MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. RESPIRATORY DISEASE TESTING MARKET: RESEARCHAI
FIGURE 30. RESPIRATORY DISEASE TESTING MARKET: RESEARCHSTATISTICS
FIGURE 31. RESPIRATORY DISEASE TESTING MARKET: RESEARCHCONTACTS
FIGURE 32. RESPIRATORY DISEASE TESTING MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 70. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 71. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 108. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 109. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES RESPIRATORY DISEASE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 137. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 138. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 139. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 140. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 141. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 142. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 143. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 146. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 147. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 148. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 149. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 150. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 151. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 152. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 153. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 154. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 155. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 156. CANADA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 162. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 163. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 164. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 165. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 166. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 167. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 168. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 169. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 170. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 171. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 172. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 173. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 174. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 175. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 176. MEXICO RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 192. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 193. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 260. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 261. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 262. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 263. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 264. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 265. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 268. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 269. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 270. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 271. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 272. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 273. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 274. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 275. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 276. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 277. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 278. GERMANY RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 279. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 280. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 281. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 282. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 283. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 284. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
TABLE 285. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 286. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 287. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 288. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 289. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
TABLE 290. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2030 (USD MILLION)
TABLE 291. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
TABLE 292. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2030 (USD MILLION)
TABLE 293. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
TABLE 294. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2030 (USD MILLION)
TABLE 295. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
TABLE 296. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2030 (USD MILLION)
TABLE 297. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
TABLE 298. FRANCE RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2030 (USD

Samples

Loading
LOADING...

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomérieux PLC
  • Charles River Laboratories
  • COSMED srl
  • Eurofins Viracor, LLC
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings
  • GE Healthcare
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MGC Diagnostics Corporation by Caire Inc.
  • QIAGEN Group
  • ResMed
  • SDI Diagnostics, Inc.
  • Seegene Inc.
  • Seimens Healthineers AG
  • Thermo Fisher Scientific

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.86 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.18 Billion
Compound Annual Growth Rate5.9%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test Type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030 - Product Image

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test Type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030

  • Report
  • 404 Pages
  • Global
From
Respiratory Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Respiratory Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Respiratory Disease Testing Market Report 2025 - Product Image

Respiratory Disease Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Respiratory Diagnostics Market by Diagnostic Tests (Blood Tests, Imaging Tests, Lung Function Tests), Patient Demographics (Adult, Geriatric, Pediatric), Offerings, End Users - Global Forecast 2025-2030 - Product Image

Respiratory Diagnostics Market by Diagnostic Tests (Blood Tests, Imaging Tests, Lung Function Tests), Patient Demographics (Adult, Geriatric, Pediatric), Offerings, End Users - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
Respiratory Diagnostics Market 2025-2033 - Product Image

Respiratory Diagnostics Market 2025-2033

  • Report
  • 135 Pages
  • Global
From

About the Respiratory Disease Test Market

The Respiratory Disease Test market within the context of Diagnostics is a rapidly growing sector, as respiratory diseases are among the most common illnesses worldwide. Tests for respiratory diseases are used to diagnose and monitor a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. These tests can be conducted in a variety of ways, including imaging tests, pulmonary function tests, and laboratory tests. Imaging tests such as X-rays and CT scans are used to detect abnormalities in the lungs, while pulmonary function tests measure the amount of air a person can inhale and exhale. Laboratory tests, such as sputum tests, are used to detect the presence of bacteria or viruses in the lungs. Some companies in the Respiratory Disease Test market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.